RxDoctor Payments Data

Debra Epstein, MD

Obstetrics & Gynecology · Maple Shade, NJNPI 1821060005

Payments from drug & device makers

$3,458in general payments, 2019–2025

Across 250 payments — averaging $13.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$1K
  • AbbVie$712
  • Astellas Pharma US Inc$392
  • Amgen$381
  • AMAG Pharmaceuticals, Inc.$126
  • Sumitomo Pharma America, Inc.$125
  • plus $693 from 16 others

What the payments were for

  • Food & beverage$3,11190%
  • Education$34810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,458 in reported general payments places this provider in the 85th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

See all obstetrics & gynecology providers in New Jersey

Medicare billing

Part B allowed, 2024
$252,987
Medicare patients
441
Services billed
7,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron43$49,979
ProliaDenosumab18$31,072
GemtesaVibegron23$30,052
Estradiol126$12,662
PremarinEstrogens, Conjugated30$7,390
Raloxifene Hcl45$1,963
YuvafemEstradiol13$1,945
ValacyclovirValacyclovir Hcl59$1,771
Estradiol (Twice Weekly)Estradiol11$1,477
Oxybutynin Chloride ErOxybutynin Chloride44$1,324
Alendronate Sodium130$1,089
ProgesteroneProgesterone, Micronized23$856
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet12$745
Risedronate Sodium13$640
Venlafaxine Hcl ErVenlafaxine Hcl29$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$392$49,97943 claims
AmgenProlia$381$31,07218 claims
Sumitomo Pharma America, Inc.Gemtesa$125$30,05223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

Other obstetrics & gynecology in Maple Shade

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →